1. Nelson SP, Chen EH, Syniar GM, Christoffel
KK. Prevalence of symptoms of gastroesophageal reflux during infancy.
A pediatric practice-based survey. Pediatric Practice Research Group. Arch
Pediatr Adolesc Med. 1997;151(6):569-572.
2. Martin AJ, Pratt N, Kennedy JD, et al. Natural history and
familial relationships of infant spilling to 9 years of age. Pediatrics. 2002;109(6):1061-1067.
3. Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence
of symptoms of gastroesophageal reflux during childhood: a pediatric
practice-based survey. Pediatric Practice Research Group. Arch
Pediatr Adolesc Med. 2000;154(2):150-154.
4. Treem WR, Davis PM, Hyams JS. Gastroesophageal reflux in
the older child: presentation, response to treatment and long-term
follow-up. Clin Pediatr (Phila). 1991;30(7):435-440.
5. El-Serag HB, Richardson P, Pilgrim P, Gilger MA. Childhood GERD
is a risk factor for GERD in adolescents and young adults. Am
J Gastroenterol. 2004;99(5):806-812.
6. Hassall E, Kerr W, El-Serag HB. Characteristics of children
receiving proton pump inhibitors continuously for up to 11 years
duration. J Pediatr. 2007;150(3):262-267.
7. Gerson B. A little weight gain, how much gastroesophageal
reflux disease? Gastroenterology. 2006;131(5):1644-1646.
8. Chak A, Ochs-Balcom H, Falk G, et al. Familiality in Barrett’s esophagus,
adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal
junction. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1668-1673.
9. Casson AG, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms
of microsomal epoxide hydroxylase and glutathione S-transferases
M1, T1 and P1, interactions with smoking, and risk for esophageal
(Barrett) adenocarcinoma. Cancer Detect Prev. 2006;30(5):423-431.
10. Böhmer CJ, Klinkenberg-Knol EC, Niezen-de Boer
MC, Meuwissen SG. Gastroesophageal reflux disease in intellectually
disabled individuals: How often, how serious, how manageable? Am
J Gastroenterol. 2000;95(8):1868-1872.
11. Koivusalo A, Pakarinen MP, Rintala RJ. The cumulative incidence
of significant gastroesophageal reflux in patients with oesophageal
atresia with a distal fistula—a systematic clinical, pH-metric,
and endoscopic follow-up study. J Pediatr Surg. 2007;42(2):370-374.
12. Deurloo JA, Ekkelkamp S, Bartelsman JF, et al. Gastroesophageal
reflux: prevalence in adults older than 28 years after correction of
esophageal atresia. Ann Surg. 2003;238(5):686-689.
13. Hassall E, Israel DM, Davidson AG, Wong LT. Barrett’s esophagus
in children with cystic fibrosis: not a coincidental association. Am
J Gastroenterol. 1993;88(11):1934-1938.
14. Dhillon AS, Ewer AK. Diagnosis and management of gastro-oesophageal
reflux in preterm infants in neonatal intensive care units. Acta
Paediatr. 2004;93(1):88-93.
15. Poets CF. Gastroesophageal reflux: a critical review of
its role in preterm infants. Pediatrics. 2004;113(2):e128-e132.
16. Davidson GP, Omari TI. Pathophysiological mechanisms of
gastroesophageal reflux disease in children. Curr Gastroenterol
Rep. 2001;3(3):257-262.
17. Rudolph CD, Mazur LJ, Liptak GS, et al; North American Society for
Pediatric Gastroenterology and Nutrition. Guidelines for evaluation
and treatment of gastroesophageal reflux in infants and children:
recommendations of the North American Society for Pediatric Gastroenterology
and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(suppl
2):S1-S31.
18. Moore DJ, Siang-Kuo Tao B, Lines DR, Hirte C, Heddle ML, Davidson
GP. Double-blind placebo-controlled trial of omeprazole in irritable
infants with gastroesophageal reflux. J Pediatr. 2003;143(2):219-223.
19. Vakil NB, Traxler B, Levine D. Dysphagia in patients with
erosive esophagitis: prevalence, severity, and response to proton
pump inhibitor treatment. Clin Gastroenterol Hepatol. 2004;2(8):
665-668.
20. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics
of orally administered omeprazole in children. International Pediatric Omeprazole
Pharmacokinetic Group. Am J Gastroenterol. 2000;95(11):3101-3106.
21. Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety
of
lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal
reflux disease.
J Pediatr Gastroenterol Nutr. 2005;40(3):319-327.
22. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book
L. Efficacy of
lansoprazole in the treatment of gastroesophageal
reflux disease in children.
J Pediatr Gastroenterol Nutr. 2002;35(suppl
4):S308-S318.
23. Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez
J, Yañez P. Efficacy and safety of oral pantoprazole 20
mg given once daily for reflux esophagitis in children. J
Pediatr Gastroenterol Nutr. 2003;36(2):261-265.
24. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer
GM; Members of the 322 Study Group. Multicenter, randomized, double-blind
study comparing 10, 20 and 40 mg pantoprazole in children (5-11
years) with symptomatic gastroesophageal reflux disease. J
Pediatr Gastroenterol Nutr. 2006;42(4):384-391.
25. Hassall E. Esophageal metaplasia: definition and prevalence in
childhood. Gastrointest Endosc. 2006;64(5):676-677.
26. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner
RE. Dysplasia and cancer in a large multicenter cohort of patients
with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4(5):566-572.
27. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus
Group. The Montreal definition and classification of gastroesophageal
reflux disease: a global evidence-based consensus. Am J
Gastroenterol. 2006;101(8):1900-1920.
28. Spitzer AR, Boyle JT, Tuchman DN, Fox WW. Awake apnea associated
with gastroesophageal reflux: a specific clinical syndrome. J
Pediatr. 1984;104(2):200-205.
29. Kiljander TO, Harding SM, Field SK, et al. Effects of
esomeprazole
40 mg twice daily on asthma: a randomized placebo-controlled trial.
Am
J Respir Crit Care Med. 2006;173(10):1091-1097.
30. Littner MR, Leung FW, Ballard ED 2nd, Huang B, Samra NK;
Lansoprazole
Asthma Study Group. Effects of 24 weeks of
lansoprazole therapy
on asthma symptoms, exacerbations, quality of life, and pulmonary
function in adult asthmatic patients with acid reflux symptoms.
Chest. 2005;128(3):1128-1135.
31. Størdal K, Johannesdottir GB, Bentsen BS, et al. Acid
suppression does not change respiratory symptoms in children with
asthma and gastro-oesophageal reflux disease.
Arch Dis Child. 2005;
90(9):956-960.
[PubMed: 21298792]
32. Khoshoo V, Le T, Haydel RM Jr, Landry L, Nelson C. Role
of gastroesophageal reflux in older children with persistent asthma. Chest. 2003;123(4):
1008-1013.
33. Owayed AF, Campbell DM, Wang EE. Underlying causes of recurrent
pneumonia in children. Arch Pediatr Adolesc Med. 2000;154(2):190-194.
34. Böhmer CJ, Niezen-de Boer RC, Klinkenberg-Knol
EC, Meuwissen SG. Omeprazole: therapy of choice in intellectually
disabled children. Arch Pediatr Adolesc Med. 1998;152(11):1113-1118.
35. Canani RB, Cirillo P, Roggero P, et al; Working Group on
Intestinal Infections of the Italian Society of Pediatric Gastroenterology,
Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors
increases the risk of acute gastroenteritis and community-acquired
pneumonia in children. Pediatrics. 2006;117(5):e817-e820.
36. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil
N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms
attributed to gastro-oesophageal reflux disease. Aliment
Pharmacol Ther. 2007;25(4):385-392.
37. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney
JT, Garske LA. Systematic review and meta-analysis of randomised
controlled trials of gastro-oesophageal reflux interventions for chronic
cough associated with gastro-oesophageal reflux. Br Med
J. 2006;332(7532):11-17.
38. Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in
laryngopharyngeal reflux unresponsive to aggressive acid suppression:
a controlled study. Clin Gastroenterol Hepatol. 2006;4(4):433-441.
39. De Giacomo C, Bawa P, Franceschi M, Luinetti O, Fiocca R.
Omeprazole for severe reflux esophagitis in children. J
Pediatr Gastroenterol Nutr. 1997;24(5):528-532.
40. Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety
of
lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal
reflux disease.
J Pediatr Gastroenterol Nutr. 2005;40(3):319-327.
41. Gunasekaran T, Gupta S, Gremse D, et al.
Lansoprazole in adolescents
with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics,
symptom relief efficacy, and tolerability.
J Pediatr Gastroenterol
Nutr. 2002;35(suppl 4):S327-S335.
42. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer
GM; Members of the 322 Study Group. Multicenter, randomized, double-blind
study comparing 10, 20 and 40 mg pantoprazole in children (5-11
years) with symptomatic gastroesophageal reflux disease. J
Pediatr Gastroenterol Nutr. 2006;42(4):384-391.
43. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics
of orally administered omeprazole in children. International Pediatric Omeprazole
Pharmacokinetic Group. Am J Gastroenterol. 2000;95(11):3101-3106.
44. Hoyo-Vadillo C, Venturelli CR, González H, et al.
Metabolism of omeprazole after two oral doses in children 1 to 9
months old. Proc West Pharmacol Soc. 2005:48:108-109.
45. Boccia G, Manguso F, Miele E, Buonavolontà R, Staiano
A. Maintenance therapy for erosive esophagitis in children after
healing by omeprazole: is it advisable? Am J Gastroenterol. 2007;102(6):1291-1297.
46. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound
acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment
Pharmacol Ther. 2005;21(2):149-154.
47. Böhmer CJ, Klinkenberg-Knol EC, Niezen-de Boer
MC, Meuwissen SG. Gastroesophageal reflux disease in intellectually
disabled individuals: how often, how serious, how manageable? Am
J Gastroenterol. 2000;95(8):1868-1872.
48. Cheung KM, Tse PW, Ko CH, Chan YC, Leung CY, Chan KH. Clinical
efficacy of proton pump inhibitor therapy in neurologically impaired
children with gastroesophageal reflux: prospective study. Hong
Kong Med J. 2001;7(4):356-359.
49. Lobe TE. The current role of laparoscopic surgery for gastroesophageal
reflux disease in infants and children. Surg Endosc. 2007;21(2):167-174.
50. Goessler A, Huber-Zeyringer A, Hoellwarth ME. Recurrent
gastroesophageal reflux in neurologically impaired patients after fundoplication. Acta
Paediatr. 2007;96(1):87-93.
51. Esposito C, Montupet P, van Der Zee D, et al. Long-term
outcome of laparoscopic Nissen, Toupet, and Thal antireflux procedures
for neurologically normal children with gastroesophageal reflux
disease. Surg Endosc. 2006;20(6):855-858.
52. Bufler P, Ehringhaus C, Koletzko S. Dumping syndrome: a common
problem following Nissen fundoplication in young children. Pediatr
Surg Int. 2001;17(5):351-355.
53. Richards CA, Milla PJ, Andrews PL, Spitz L. Retching and vomiting
in neurologically impaired children after fundoplication: predictive
preoperative factors. J Pediatr Surg. 2001;36(9):1401-1404.
54. Mulhall BP, Wong RK. Infectious esophagitis. Curr
Treat Options Gastroenterol. 2003;6(1):55-70.
55. Klingspor L, Stintzing G, Tollemar J. Deep Candida infection
in children with leukaemia: clinical presentations, diagnosis and
outcome. Acta Paediatr. 1997;86(1):30-36.
56. Simon MR, Houser WL, Smith KA, Long PM. Esophageal candidiasis
as a complication of inhaled corticosteroids. Ann Allergy
Asthma Immunol. 1997;79(4):333-338.
57. Rahhal RM, Ramkumar DP, Pashankar DS. Simultaneous herpetic
and candidal esophagitis in an immunocompetent teenager. J
Pediatr Gastroenterol Nutr. 2005;40(3):371-373.
58. Chiou CC, Groll AH, Gonzalez CE, et al. Esophageal candidiasis
in pediatric acquired immunodeficiency syndrome: clinical manifestations
and risk factors. Pediatr Infect Dis J. 2000;19(8):729-734.
59. Uc A, North P, Burks W. Esophageal candidiasis in an infant
with reflux esophagitis. J Pediatr Gastroenterol Nutr. 2000:31(5):572-574.
60. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ,
Sable CA. A randomized double-blind study of caspofungin versus
amphotericin for the treatment of candidal esophagitis. Clin
Infect Dis. 2001;33(9):1529-1535.
61. McKenna DP, Triner W, Tomassi M, Poonthota A. Herpes simplex
virus esophagitis in an immunocompetent teenaged girl. Am
J Emerg Med. 2006;24(7):902-904.
62. Rodrigues F, Brandão N, Duque V, Ribeiro C, António
AM. Herpes simplex virus esophagitis in immunocompetent children. J
Pediatr Gastroenterol Nutr. 2004;39(5):560-563.
63. Harada N, Shimada M, Suehiro T, et al. Unusual endoscopic findings
of CMV esophagitis after liver transplantation. Hepatogastroenterology. 2005;52(64):1236-1239.
64. Trappe R, Pohl H, Forberger A, Schindler R, Reinke P. Acute esophageal
necrosis (black esophagus) in the renal transplant recipient: manifestation
of primary cytomegalovirus infection. Transpl Infect Dis. 2007;9(1):42-45.
65. Bini EJ, Micale PL, Weinshel EH. Natural history of HIV-associated
esophageal disease in the era of protease inhibitor therapy. Dig
Dis Sci. 2000;45(7):1301-1307.
66. Siegmund B, Moos V, Loddenkemper C, Wahnschaffe U, Engelmann
E, Zeitz M. Esophageal giant ulcer in primary human immunodeficiency
virus infection is associated with an infiltration of activated
T cells. Scand J Gastroenterol. 2007;42(7):890-895.
67. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence,
prevention and management. Drug Saf. 2000;22(3):237-234.
68. Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced
pill esophagitis. Dis Esophagus. 2004;17(2):168-171.
69. Dogan Y, Erkan T, Çokugras FC, Kutlu T. Caustic gastroesophageal
lesions in childhood: an analysis of 473 cases. Clin Pediatr
(Phila). 2006;45(5):435-438.
70. Crain EF, Gershel JC, Mezay AP. Caustic ingestion. Symptoms as
predictors of esophageal injury.
Am J Dis Child. 1984;138:863-865.
[PubMed: 6475876]
71. Gaudreault P, Parent M, McGuigan MA, et al. Predictability
of esophageal injury from signs and symptoms: a study of caustic ingestion
in 378 children. Pediatrics. 1983;71(5):767-770.
72. Christesen HBT. Prediction of complications following unintentional
caustic ingestion in children. Is endoscopy always necessary? Acta
Paediatrica. 1995;84(10):1177-1182.
73. Aronow SP, Aronow HD, Blanchard T, Czinn S, Chelimsky G.
Hair relaxers: a benign caustic ingestion? J Pediatr Gastroenterol
Nutr. 2003;36(1):120-125.
74. Ahsan S, Haupert M. Absence of esophageal injury in pediatric patients
after hair relaxer ingestion. Arch Otolaryngol Head Neck Surg. 1999;125(9):953-955.
75. Zargar SA, Kochhar R, Mehta S, et al. The role of fiberoptic
endoscopy in the management of corrosive ingestion and modified endoscopic
classification of burns. Gastrointest Endosc. 1991;37(2):165-169.
76. Baskin D, Urganci N, Abbasolu L, et al. A standardised protocol
for the acute management of corrosive ingestion in children. Pediatr
Surg Int. 2004;20(11):824-828.
77. Anderson KD, Rouse TM, Randolph JG. A controlled trial of corticosteroids
in children with corrosive injury of the esophagus. N Engl
J Med. 1990;323(10):637-640.
78. Pelclová D, Navrátil T. Do corticosteroids
prevent oesophageal stricture after corrosive ingestion? Toxicol
Rev. 2005;24(2):125-129.
79. Ilkin Naharci M, Tuzun A, Erdil A, et al. Effectiveness
of bougie dilation for the management of corrosive esophageal strictures. Acta
Gastroenterol Belg. 2006;69(4):372-376.
80. Erdoan E, Emir H, Erolu E, Danimend N, Yeker D. Esophageal
replacement using the colon: a 15-year review. Pediatr Surg
Int. 2000;16(8):546-549.
81. Atabek C, Surer I, Demirbag S, Caliskan B, Ozturk H, Cetinkursun
S. Increasing tendency in caustic esophageal burns and long-term
polytetrafluorethylene stenting in severe cases: 10 years experience. J
Pediatr Surg. 2007;42(4):636-640.
82. Katzka DA. Caustic injury to the esophagus. Curr
Treat Options Gastroenterol. 2001;4(1):59-66.
83. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson
HA. Eosinophilic esophagitis attributed to gastroesophageal reflux:
improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503-1512.
84. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic
esophagitis in children and adults: a systematic review and consensus recommendations
for diagnosis and treatment. Gastroenterology. 2007;133(4):1342-1363.
85. Furuta GT, Straumann A. Review article: the pathogenesis
and management of eosinophilic oesophagitis. Aliment Pharmacol
Ther. 2006;24(2): 173-182.
86.
Mepolizumab: 240563, Anti-IL-5 Monoclonal Antibody—GlaxoSmithKline,
Anti-Interleukin-5 Monoclonal Antibody—GlaxoSmithKline,
SB 240563.
Drugs R D. 2008;9(2):125-130.
87. Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in
eosinophilic esophagitis: transcriptome analysis and reversibility
with glucocorticoids.
J Allergy Clin Immunol. 2007;
120(6):1292-1300.
[PubMed: 18073124]
88. Pentiuk SP, Miller CK, Kaul A. Eosinophilic esophagitis
in infants and toddlers. Dysphagia. 2007;22(1):44-48.
89. Smith CR, Miranda A, Rudolph CD, Sood MR. Removal of impacted
food in children with eosinophilic esophagitis using Saeed banding
device. J Pediatr Gastroenterol Nutr. 2007;44(4):
521-523.
90. Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis:
a 10-year experience in 381 children. Clin Gastroenterol
Hepatol. 2005;3(12):1198-1206.
91. Sundaram S, Sunku B, Nelson SP, et al. Adherent white plaques: an
endoscopic finding in eosinophilic esophagitis. J Pediatr
Gastroenterol Nutr. 2004;38(2):208-212.
92. Chang F, Anderson S. Clinical and pathological features
of eosinophilic esophagitis: a review. Pathology. 2008;40(1):3-8.
93. Ruchelli E, Wenner W, Voytek T, Brown K, Liacouras C. Severity of
esophageal eosinophilia predicts response to conventional gastroesophageal
reflux therapy.
Pediatr Dev Pathol. 1999; 2(1):15-18.
[PubMed: 9841701]
94. Walsh SV, Antonioli DA, Goldman H, et al. Allergic esophagitis
in children: a clinicopathological entity. Am J Surg Pathol. 1999;23(4):390-396.
95. Nurko S, Rosen R. Esophageal dysmotility in patients who
have eosinophilic esophagitis. Gastrointest Endosc Clin
N Am. 2008;18(1):73-89.
96. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination
diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin
Gastroenterol Hepatol. 2006;4(9):1097-1102.
97. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison
of oral prednisone and topical
fluticasone in the treatment of eosinophilic
esophagitis: a randomized trial in children.
Clin Gastroenterol
Hepatol. 2008;6(2):165-173.
98. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous
budesonide:
a potential new therapy for eosinophilic esophagitis in children.
Am
J Gastroenterol. 2007;102(10):2271-2279.
99. Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis
in children: immunopathological analysis and response to
fluticasone
propionate.
Gastroenterology. 2002; 122(5):1216-1225.
[PubMed: 11984507]
100. Liacouras CA, Bonis P, Putnam PE, et al. Summary of the First
International Gastrointestinal Eosinophil Research Symposium. J
Pediatr Gastroenterol Nutr. 2007;45(3):370-391.